DYN - NASDAQ

Dyne Therapeutics, Inc.

DYN·NASDAQ

$17.99

-3.4%

HealthcareBiotechnology

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.97B

EPS-3.4700

P/E Ratio-5.18

Earnings Date07/27/2026

1.19B

Assets

72%

3Y+287.0%

5Y+236.0%

10Y-91.0%

214.83M

Total Liabilities

250%

3Y+298.0%

5Y+1859.0%

10Y-98.0%

972.13M

Total Equity

54%

3Y+285.0%

5Y+184.0%

10Y-52.0%

Dyne Therapeutics, Inc. Funding & Solvency Profile

DYN · NASDAQ

Current Assets

Cash & Cash Equivalents893.37M

Net Receivables0.00

Inventory0.00

Other Current Assets16.02M

Total Current Assets1 B

Non-Current Assets

Property, Plant & Equipment44.77M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets15.60M

Total Non-Current Assets60 M

Total Assets

1.19B

Financial Health Analysis

Current Ratio

22.25x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.22x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

1 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

95% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Dyne Therapeutics, Inc. Balance Sheet

DYN • NASDAQ

Dyne Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	893.4M	435.4M	121.6M	172.1M	200.8M	300.9M	14.6M	8.1M	365M	1.8B	505M	1.9B	843M	348M	396M	291M	471M	693M	328M
Short-Term Investments	217.2M	206.8M	1.5M	83.9M	175.7M	44.5M	0.0	0.0	32M	130M	100M	78M	25M	13M	69M	106M	78M	87M	104M
Cash & Short-Term Investments	1.1B	642.3M	123.1M	256M	376.6M	345.3M	14.6M	8.1M	397M	1.9B	605M	1.9B	868M	361M	465M	397M	549M	780M	432M
Net Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	513M	386M	402M	270M	420M	108M	6M	230M	212M	340M	426M
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	445M	445M	597M	208M	181M	101M	57M	121M	141M	184M	199M
Prepaids	0.0	0.0	0.0	0.0	5.8M	3.8M	127K	34K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	16M	17M	6.3M	9.6M	0.0	0.0	0.0	0.0	169M	250M	341M	248M	216M	473M	144M	1.5B	1.1B	1.5B	606M
Total Current Assets	1.1B	659.3M	129.4M	265.6M	382.4M	349.1M	14.8M	8.2M	1.5B	3B	1.9B	2.7B	1.7B	1B	672M	2.2B	2B	2.8B	1.7B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	44.8M	30M	33.4M	38.4M	41M	1.9M	1.5M	110K	8.9B	7.1B	8.3B	3.3B	3.3B	3B	3.3B	6.3B	9.1B	10.9B	10.7B
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	772M	799M	797M	0.0	0.0	0.0	0.0	0.0	0.0	433M	438M
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25M	38M	102M	27M	108M	271M	0.0	141M	380M	437M	497M
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	797M	837M	899M	27M	108M	271M	0.0	141M	380M	870M	935M
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26M	16M	18M	2M	11M	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	571M	427M	0.0	20M	100M	18M	5M	12M	0.0	0.0	0.0
Other Non-Current Assets	15.6M	1.9M	2.3M	2.3M	2.3M	2.3M	191K	0.0	-31M	1.7B	330M	5.3B	72M	181M	116M	1.3B	-536M	-329M	-66M
Total Non-Current Assets	60.4M	32M	35.7M	40.7M	43.3M	4.2M	1.7M	110K	10.2B	10.1B	9.6B	8.6B	3.6B	3.5B	3.5B	7.8B	8.9B	11.4B	11.6B
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0	1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	1.2B	691.2M	165.1M	306.3M	425.7M	353.3M	16.4M	8.3M	11.8B	13.1B	11.5B	11.2B	5.3B	4.5B	4.1B	10B	11B	14.2B	13.2B
LIABILITIES
CURRENT LIABILITIES
Total Payables	8.1M	6.6M	22.9M	5.3M	4M	3.4M	1.3M	518K	367M	332M	292M	216M	329M	112M	15M	134M	181M	303M	292M
Accounts Payable	8.1M	6.6M	22.9M	5.3M	4M	3.4M	1.3M	518K	367M	332M	292M	216M	329M	112M	15M	134M	181M	303M	292M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-367M	-332M	-292M	-216M	-329M	-112M	-15M	-134M	-181M	-303M	-292M
Accrued Expenses	0.0	0.0	23.4M	18.2M	20.8M	7.5M	540K	184K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short Term Debt	5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	105M	201M	83M	31M	13M	29M	4M	148M	807M	64M	51M
Capital Lease Obligations (Current)	0.0	4.9M	4.7M	4.6M	3.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	64M	3M	3M	4M	274M	1M	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7M	5M	29M	20M	100M	95M	5M	12M	6M	6M	45M
Other Current Liabilities	37.5M	30.8M	0.0	0.0	0.0	0.0	562K	9K	570M	378M	408M	414M	279M	111M	135M	1.3B	853M	1.3B	611M
Total Current Liabilities	50.6M	42.3M	51.1M	28.1M	28.7M	11M	2.4M	711K	1B	916M	812M	681M	721M	347M	159M	1.6B	1.8B	1.7B	999M
NON-CURRENT LIABILITIES
Long Term Debt	15.3M	0.0	0.0	0.0	0.0	0.0	0.0	3.4M	8.3B	8.8B	7.2B	7.1B	2B	1.4B	584M	4.4B	807M	64M	51M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7M	5M	29M	20M	100M	95M	5M	641M	0.0	0.0	0.0
Other Non-Current Liabilities	148.9M	0.0	0.0	0.0	0.0	0.0	42K	9.1M	146M	170M	183M	217M	178M	257M	145M	336M	359M	500M	388M
Total Non-Current Liabilities	164.2M	19.1M	22.7M	25.9M	28.7M	0.0	42K	12.4M	8.5B	9B	7.4B	7.3B	2.3B	1.7B	734M	5.4B	1.2B	564M	439M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	340M	1.1B	388M	216M	103M	-53M	2.1B	299M	5B	7.5B	7.3B
Capital Lease Obligations	0.0	24M	27.4M	30.5M	32.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	214.8M	61.4M	73.8M	54M	57.5M	11M	2.4M	13.1M	9.9B	11B	8.6B	8.2B	3.1B	2B	3B	7.3B	8B	9.7B	8.7B
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	27.4M	9.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	16K	10K	6K	6K	6K	5K	1K	1K	1M	1M	1M	1M	1M	1M	1M	1M	6M	5M	5M
Additional Paid-In Capital	0.0	1.6B	723.8M	649.5M	596.9M	421.6M	6.4M	7K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Retained Earnings	-1.4B	-949.9M	-632.5M	-396.6M	-228.5M	-79.2M	-19.7M	-4.9M	-1.9B	-1.9B	-686M	-736M	-463M	-107M	-4.8B	-3.2B	0.0	0.0	0.0
Accumulated Other Comprehensive Income/Loss	0.0	6K	0.0	-571K	-269K	-27K	0.0	-24K	32M	21M	19M	20M	58M	11M	-53M	-53M	-150M	-215M	-25M
Other Total Stockholders' Equity	2.4B	0.0	0.0	0.0	0.0	0.0	0.0	-9M	3.7B	3.9B	3.6B	3.7B	2.6B	2.6B	6B	6B	3B	4.7B	4.5B
Total Stockholders' Equity	972.1M	629.8M	91.3M	252.4M	368.2M	342.4M	14M	-4.9M	1.9B	2B	2.9B	3B	2.2B	2.5B	1.1B	2.7B	2.9B	4.5B	4.5B
Total Equity	972.1M	629.8M	91.3M	252.4M	368.2M	342.4M	14M	-4.9M	1.9B	2B	2.9B	3B	2.2B	2.5B	1.1B	2.7B	2.9B	4.5B	4.5B
SUMMARY
Total Liabilities & Equity	1.2B	691.2M	165.1M	306.3M	425.7M	353.3M	16.4M	8.3M	11.8B	13.1B	11.5B	11.2B	5.3B	4.5B	4.1B	10B	11B	14.2B	13.2B
Total Investments	217.2M	206.8M	1.5M	83.9M	175.7M	44.5M	0.0	0.0	58M	146M	118M	80M	36M	13M	69M	106M	78M	87M	104M
Total Debt	20.3M	24M	27.4M	30.5M	32.6M	0.0	0.0	3.4M	8.4B	9B	7.3B	7.1B	2B	1.4B	588M	4.6B	1.6B	128M	102M
Net Debt	-873.1M	-411.5M	-94.2M	-141.7M	-168.2M	-300.9M	-14.6M	-4.7M	8.1B	7.2B	6.8B	5.2B	1.1B	1.1B	192M	4.3B	1.1B	-565M	-226M
Shares Outstanding	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687	142,824,687

SEC Filings

DYN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	April 22, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 02, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 23, 2025	December 22, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 10, 2025	December 09, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 08, 2025	2025	View Filing

Showing 1 to 10 of 91 filings

Related Guides

Blog Categories

Continue your DYN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.